Category Archives: Central and Eastern Europe
The ongoing search for the better early-stage clinical trial location: a case study on Australia and Georgia
International biotech and medtech companies are constantly searching for optimal locations for their early stage and proof-of-concept clinical trials. An example of a location that has become increasingly popular is Australia. This is in large part due to the great … Continue reading
Clinical Accelerator announces collaboration with Reprieve Cardiovascular for developing a Cardiovascular system to treat Acute Decompensated Heart Failure
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Reprieve Cardiovascular, LLC for conducting a study aimed at optimally decongesting patients with Acute Decompensated Heart Failure (ADHF). The study will … Continue reading
Clinical Accelerator collaborates with Thrombolytic Science International to study a tPA/mutant pro-urokinase dual regimen for thrombolysis in acute myocardial infarction
Clinical Accelerator, a full-service contract research organization, has entered into a collaboration with Thrombolytic Science International (TSI) to conduct a phase II randomised, multi-centre, open-label, parallel group mechanistic study using TSI’s dual treatment regimen in patients with ST elevation myocardial … Continue reading
VisCardia Announces Completion of Enrollment and Three Month Follow-Up Visits for Its VisONE® Heart Failure Pilot Study
Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on April 22, 2019 PORTLAND, Ore.–(BUSINESS WIRE)–VisCardia Inc., a privately held medical device developer, announced today it has completed enrollment and three month follow-up visits of the company’s … Continue reading
Clinical Accelerator announces collaboration with Archivel Farma in a phase IIa Clinical Trial for RUTI®: a therapeutic vaccination against Multi-Drug Resistant Tuberculosis
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Archivel Farma, for conducting a phase IIa clinical trial for their therapeutic vaccine RUTI® against multi-drug Resistant tuberculosis. The double-blind, randomized … Continue reading
The World’s First VisONE® Implantation: a promising start
Below, we are re-publishing with permission the press-release issued by the Heart Institute on the 28th of September 2018 “Thanks to the efforts of the study team from the Heart Institute, we have conducted the first worldwide implantation of the VisONE … Continue reading
Clinical Accelerator announces collaboration with Oncolix for developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Oncolix, for conducting clinical studies for its analogue protein, Prolanta, to treat ovarian cancer. The trials will be conducted in the … Continue reading
VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure
Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on the 1st of August 2018 PORTLAND, Ore.–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and … Continue reading
FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe
Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of that region: Bulgaria, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation, and the Ukraine (listed alphabetically). The … Continue reading
ARREST Phase IIb Top-Line 52 weeks results
Below, we are re-publishing with permission the press-release issued by Galmed Pharmaceuticals Ltd. on the 12th of June 2018 Galmed’s 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global … Continue reading
